Profile data is unavailable for this security.
About the company
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
- Revenue in USD (TTM)93.38m
- Net income in USD-551.73m
- Incorporated2021
- Employees999.00
- LocationAlvotech SA9, Rue De BitbourgLUXEMBOURG 1273LuxembourgLUX
- Websitehttps://www.alvotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | 7.29m | -55.59m | 3.19bn | 64.00 | -- | 4.86 | -- | 437.60 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | -- | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 3.20bn | 124.00 | -- | -- | -- | 206.15 | -2.00 | -2.00 | 0.2416 | -- | -- | -- | -- | 125,032.30 | -- | -19.17 | -- | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | -- | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.26bn | 18.00k | -- | 1.86 | 35.05 | 1.05 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.28bn | 251.00 | -- | 3.53 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.39bn | 305.00 | -- | 5.97 | -- | 128.13 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.49bn | 1.28k | -- | 24.86 | -- | 7.88 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.65bn | 545.00 | -- | 25.35 | -- | 14.56 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Biohaven Ltd | 0.00 | -408.17m | 3.66bn | 239.00 | -- | 7.86 | -- | -- | -5.67 | -5.67 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -69.48 | -- | -79.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Alvotech SA | 93.38m | -551.73m | 3.70bn | 999.00 | -- | -- | -- | 39.60 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -614.93m | 3.73bn | 105.00 | -- | 47.96 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.73bn | 271.00 | 26.78 | 2.26 | 23.04 | 2.95 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.75bn | 290.00 | -- | 6.03 | -- | 935.20 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Insmed Inc | 305.21m | -749.57m | 3.87bn | 912.00 | -- | -- | -- | 12.69 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.91bn | 557.00 | -- | 6.13 | -- | 3,290.20 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 4.16bn | 2.10k | 7.02 | 3.32 | 6.26 | 2.41 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Data as of May 08 2024. Currency figures normalised to Alvotech SA's reporting currency: US Dollar USD
7.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Oaktree Capital Management LPas of 31 Dec 2023 | 5.45m | 2.04% |
| Bracebridge Capital LLCas of 31 Dec 2023 | 4.36m | 1.63% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.40m | 0.90% |
| Shinhan Securities Co., Ltd. (Private Banking)as of 31 Dec 2022 | 1.49m | 0.56% |
| IS Funds Ltd.as of 31 Dec 2022 | 1.24m | 0.47% |
| Littlejohn & Co. LLC (Investment Management)as of 31 Dec 2023 | 1.13m | 0.42% |
| Sculptor Capital LPas of 31 Dec 2023 | 1.09m | 0.41% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2023 | 1.00m | 0.38% |
| Kvika eignast�ring hf.as of 31 Dec 2022 | 994.60k | 0.37% |
| Stefnir hfas of 31 Dec 2022 | 745.95k | 0.28% |
More ▼
Data from 31 Dec 2023 - 04 Apr 2024Source: FactSet Research Systems Inc.
